Rutherford Health - Start of radiotherapy services in Liverpool
RNS Number : 7876N
Rutherford Health PLC
03 February 2021
 

Rutherford Health Plc

Rutherford Health announces start of radiotherapy services in Liverpool

London, 03 February, 2021: Rutherford Health plc (the "Company" or "Group" or "Rutherford") is pleased to announce that its centre in Liverpool, the Rutherford Cancer Centre North West, has been approved by the Care Quality Commission to treat patients with radiotherapy.

The centre opened last summer and to date has been offering patients Systemic Anti-Cancer Therapy (SACT) services which include chemotherapy, immunotherapy, targeted therapies symptom control as well as blood tests, oncology nurse consultation, supportive therapies and diagnostic services. Commencement of radiotherapy treatment will significantly enhance the centre's offering.

The Rutherford Cancer Centre North West provides a significant step forward for cancer care in the region as it is equipped with an Elekta Unity MR-Linac in addition to an Elekta Versa HD linac. The Elekta Unity MR Linac combines a linear accelerator with an integrated Philips MR Scanner and is at the forefront of radiotherapy technology providing the highest quality image guided radiotherapy with online adaptive re-planning.

It is currently expected that high energy proton beam therapy equipment will be installed at the centre later this year with first patients treated in 2022, which will make the centre one of the most advanced cancer therapy facilities in Europe.

Mike Moran, CEO of Rutherford Health, said: "We are delighted to bring MR Linac to Liverpool. It heralds a significant step forward for advanced cancer care services in the region and will be the first in the Liverpool City Region. Our network of cancer centres continues to play a key role in providing cancer care across the UK, especially in relation to precision radiotherapy."

Services at the Rutherford Cancer Centre North West will be accessible to private patients under medical insurance, self-pay patients and to NHS patients where NHS contracts are in place.

 

The Directors of the Company accept responsibility for the contents of this announcement.

 

Contacts:

Rutherford Health plc
Michael Moran, Chief Executive Officer             

Tel: +44 (0) 16 3381 0661         

 

Grant Thornton (Corporate Adviser)
Colin Aaronson / Jamie Barklem       

Tel: +44 (0) 20 7383 5100              

Media House International
Ramsay Smith    
ramsay@mediahouse.co.uk

Tel: 07788 414 856 or
        0207 710 0020 

 

 

About Rutherford Health plc

Rutherford Health Plc operates a network of Rutherford Cancer Centres which offer the latest cancer therapies including proton beam therapy. Its centre in Wales introduced proton beam therapy to the UK and was the first to treat a cancer patient with the pioneering treatment in the UK in 2018. It also has centres in Reading, Northumberland and Liverpool. The combined centres boast a centrally networked management system which allows patients to be treated at any Rutherford centre after they have been screened.

For more information on the Rutherford Cancer Centres, please visit: http://www.therutherford.com

Follow the Rutherford Cancer Centres on twitter: @therutherford_c

 

 

This information is provided by RNS, the news service of the . RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXTTMBTMTAMTFB ]]>